510(k) Report

510(k) · Cleared

Cleared

Bindazyme Anti-Tissue Transglutaminase Iga Eia

K993612510(k) TraditionalCleared Dec 21, 199957-day reviewClass II21 CFR 866.5660

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

The Binding Site, Ltd. · MVM Autoantibodies, Endomysial (Tissue Transglutaminase)

Cleared on Dec 21, 1999 after a 57-day review. FDA’s file for it is a 510(k) statement, which names no predicate. 1 later device descends from it.

Decided
Dec 21, 1999
Review
57 days
Class
Class II
Product code
MVM
Recalls
None
Predicates
0

1 later device descends from it, 1 citing it directly.

Descendants, by year cleared 2004: 1 descendant cleared1995200020052010201520202025
  1. This deviceK993612 Bindazyme Anti-Tissue Transglutaminase Iga EiaThe Binding Site, Ltd. · 1999
  2. Descendant · cites it directly · 0 of its ownK041002 Fidis CeliacBiomedical Diagnostics S.A. · 2004

Most influential descendants

Showing 1 of 1 · See all
  • K041002Fidis CeliacBiomedical Diagnostics S.A. · 2004 · cites it directly0descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
0 (this device)K993612Bindazyme Anti-Tissue Transglutaminase Iga EiaThe Binding Site, Ltd.1999—
+1K041002Fidis CeliacBiomedical Diagnostics S.A.2004—

Descendants by year cleared

Year clearedDevicesWith a Class I recall
200410
FIG. 1 — Lineage of K993612, 1999–2004Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA 510(k) statement (indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in MVM? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new MVM device

  1. #1 K200230 Aptiva Celiac Disease IgG Reagentscore 2.2 · 2 generations · no Class I recall
  2. #2 Held for the reportin the report
Get a 510(k) Report

What was it cleared against?

FDA’s file for it is a 510(k) statement, which names no predicate.

What descends from it? (1)

1 later device cites it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K041002Fidis CeliacBiomedical Diagnostics S.A.20040

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • Of its descendants, K041002 (Biomedical Diagnostics S.A., 2004) has gone furthest, with 0 descendants of its own.

How does its category compare?

All MVM devices

MVM Autoantibodies, Endomysial (Tissue Transglutaminase): FDA decisions, review times, recalls and adverse event reports over 20 years.

FDA decisions per year · MVM

2in 2021

2007: 22008: 32010: 22011: 32013: 22014: 12019: 22021: 2
2007high 3 (2008) · low 0 (2009)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · MVM

275in 2011

2008: 98 days median2011: 275 days median
2007high 275 (2011) · low 98 (2008)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · MVM

No recall names MVM since 2007.

Adverse event reports per year · MVM

1in 2024

2017: 12024: 1
2007high 1 (2017) · low 0 (2007)2025

MAUDE reports naming product code MVM, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20072—00
200839800
20090—00
20102—00
2011327500
20120—00
20132—00
20141—00
20150—00
20160—00
20170—01
20180—00
20192—00
20200—00
20212—00
20220—00
20230—00
20240—01
20250—00
20260—0—

What is it indicated for?

The in-vitro measurement of specific autoantibodies against tissue transglutaminase (tTG) present in human serum, as an aid in the diagnosis of Coeliac disease.

Indications for use read by OCR from a scanned FDA 510(k) statement, so letters may be misread. Check the PDF before quoting it.

Cite this page

510(k) Report. “K993612: Bindazyme Anti-Tissue Transglutaminase Iga Eia.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K993612

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026